FDA Broad Agency Announcement for Advanced Research and Development of Regulatory Science (FY26: FDABAA-26-00123)
FDA Broad Agency Announcement for Advanced Research and Development of Regulatory Science (FY26: FDABAA-26-00123) is a funding call from U.S. Food and Drug Administration that has no fixed deadline (rolling). Funding: not stated in source data — see the official call. Eligibility: Concept paper plus full proposal required; R&D contracts up to five years; eligibility per BAA text.
- Funder
- U.S. Food and Drug Administration
- Deadline
- Recurring call (closed for FY26 (response date 24 Feb 2026; notice inactive 30 Sep 2026); recurring annually): check the funder page for the next date.
- Status
- Recurring
- Amount
- Not stated in source data — see call
- Region / eligibility
- US (contracts; check BAA for foreign eligibility)
- Career stage
- established / PI
- Fields
- crystallization, pharma process, chemistry
- Reference
- —
- Official call
- Funder page (curated calendar) listing
Eligibility in plain language
Concept paper plus full proposal required; R&D contracts up to five years; eligibility per BAA text.
Who should apply
Crystal growth / crystallization researchers, medicinal chemists and pharma process / drug-development teams, synthetic, physical and analytical chemists — best fit for PIs and research groups.
Summary from source
Agency-wide BAA; FY26 topics include 'Advanced Manufacturing Approaches' and 'Analytical and Computational Methods'. FDA's yearly BAA incl. Advanced Manufacturing Approaches. FY26 closed 24 Feb 2026; FDA says it targets posting each year's BAA in November. FY27 BAA not yet on SAM.gov as of 16 Oct 2026.